ReviewDermatologie (Heidelberg, Germany)2026
[Rosai-Dorfman Syndrome-a diverse clinical spectrum].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosai-Dorfman syndrome is a rare disease that belongs to the group of non-Langerhans cell histiocytosis. Affected patients can exhibit a wide variety of symptoms, which can be divided into nodal and extranodal manifestations. The syndrome primarily presents with fever, enlarged lymph nodes, and weight loss. Extranodal findings may include pancreatic cysts, hypergammaglobulinemia, and infiltration of testicular tissue. Skin involvement occurs in approximately one-third of cases. In addition to routine beside histopathology, immunohistochemistry with positivity for S100 and CD68 and negativity for CD 1a is particularly decisive for diagnosis. Topical and/or systemic steroids are used as first-line treatment for skin manifestations. In individual case studies, other systemic therapies have been used. Other treatment options include methotrexate (MTX), sirolimus, or rituximab. If KRAS/MAP2K1 mutation is detected, treatment with MEK inhibitors may be considered.
Indexed as
Identifiers
41917173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.